Skip to main content

Table 1 Demographic information of participants from the ROS/MAP cohort

From: miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease

 

NCI

(n = 102)

AD

(n = 177)

Total

(n = 702)

P value b

Female

54 (52.9)

126 (71.2)

449 (64.1)

0.002

Age at death in years a

85.0 (78.8–89.0)

90.0 (87.4–90.0)

88.5 (84.1–90.0)

< 0.001

Study

    

 ROS

53 (52.0)

93 (52.5)

381 (54.4)

 

 MAP

49 (48.0)

84 (47.5)

320 (45.6)

0.926

Global cognitive Z scores at the last visit a

0.10 (-0.25–0.36)

-0.35 (-0.93–0.06)

-0.17 (-0.56–0.19)

< 0.001

Slope of global cognitive Z scores a

-0.03 (-0.13 – 0.02)

-0.17 (-0.30 – -0.08)

-0.09 (-0.22 – -0.01)

< 0.001

RNA integrity numbers a

7.3 (6.0–8.0)

6.7 (5.4–7.4)

6.9 (5.6–7.7)

0.001

Post-mortem interval in hours a

6.3 (4.8–8.6)

5.8 (4.2–8.3)

5.8 (4.3–8.5)

0.124

  1. Values are n (%), unless indicated otherwise. Among a total of 702 participants with miRNA data, 177 subjects met criteria for AD and 102 met criteria for NCI based on neuropathological and clinical data
  2. AD Alzheimer’s dementia, MAP Memory and Aging Project, miRNAs microRNAs, NCI no cognitive impairment, ROS Religious Orders Study
  3. aData are presented as median (interquartile range)
  4. bThe Mann–Whitney U test or chi-square test was used to determine the P value for comparisons between AD and NCI groups, as appropriate